Results 21 to 30 of about 369,109 (345)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS

open access: yesJurnal Urologi Indonesia, 2016
Objective: In Hasan Sadikin General Hospital Bandung prostate biopsy is recommended for patients with prostate specific antigen (PSA) levels above 10 ng/mL or PSA density (PSAD) above 0.15 if PSA in between 4–10 ng/mL.
Daniel Simanjuntak, Ferry Safriadi
doaj   +1 more source

Components of cell-matrix linkage as potential new markers for prostate cancer [PDF]

open access: yes, 2011
Prostate cancer is one of the most common tumor diseases worldwide. Often being non-aggressive, prostate tumors in these cases do not need immediate treatment.
Eble, Johannes Andreas, Navdaev, Alexey
core   +2 more sources

Evaluation of Phage Display Discovered Peptides as Ligands for Prostate-Specific Membrane Antigen (PSMA) [PDF]

open access: yes, 2013
The aim of this study was to identify potential ligands of PSMA suitable for further development as novel PSMA-targeted peptides using phage display technology. The human PSMA protein was immobilized as a target followed by incubation with a 15-mer phage
A Ghosh   +48 more
core   +11 more sources

Accuracy of elastic fusion biopsy in daily practice: results of a multicenter study of 2115 patients [PDF]

open access: yes, 2018
OBJECTIVES: To assess the accuracy of Koelis fusion biopsy for the detection of prostate cancer and clinically significant prostate cancer in the everyday practice.
Albisinni S   +30 more
core   +1 more source

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer

open access: yesProstate International, 2013
Racial differences exist in the incidence of prostate cancer (PCa). Although many studies have looked at the performance of prostate-specific antigen (PSA) and PSA density (PSAD) in the detection of PCa, only a few have looked at it in relation to ...
Ahmad Anies Shahab   +5 more
doaj   +1 more source

Oral ethinylestradiol in castration resistent prostate cancer: 10 year experience [PDF]

open access: yes, 2015
To describe our 10-year experience with the use of oral ethinylestradiol in the treatment of metastatic castration-resistant prostate cancer. METHODS: From February 2000 to April 2010, 116 patients with a metastatic castration-resistant prostate cancer
Aggarwal   +16 more
core   +1 more source

Prostate specific antigen in a community-based sample of men without prostate cancer: Correlations with prostate volume, age, body mass index, and symptoms of prostatism [PDF]

open access: yes, 1995
The correlation between both prostate specific antigen levels (PSA) and prostate specific antigen density (PSAD) and age, prostate volume parameters, body mass index, and the International Prostate Symptom Score (IPSS) were studied in a community‐based ...
Bangma, C.H. (Chris)   +4 more
core   +2 more sources

A cross-sectional comparison of quality of life between physically active and underactive older men with prostate cancer [PDF]

open access: yes, 2016
Men with prostate cancer experience many side effects and symptoms that may be improved by a physically active lifestyle. It was hypothesized that older men with prostate cancer who were physically active would report significantly higher levels of ...
Boisen, Samara   +8 more
core   +1 more source

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia

open access: yesAsian Journal of Andrology, 2015
In Western countries, clinical trials on prostate cancer screening demonstrated a limited benefit for patient survival. In the Asia-Pacific region, including Japan, the rate of prostate-specific antigen (PSA) testing remains very low compared with ...
Yasuhide Kitagawa, Mikio Namiki
doaj   +1 more source

Emerging treatments for recurrent prostate cancer [PDF]

open access: yes, 2015
Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we focus on how these will specifically benefit those men with recurrent disease.
Hanna, Catherine, Jones, Robert J.
core   +1 more source

Home - About - Disclaimer - Privacy